Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine.
Laboratory parameters which are modified following administration of zidovudine are becoming increasingly useful in monitoring the efficacy of treatment of early stages of HIV-1 infection. The serum levels of soluble interleukin (sILR)-2 receptor, which have been reported to increase early in HIV-1 infection, were found to be significantly lower in 24 patients being treated with zidovudine than in 69 patients who were not treated, 28 of whom had CD4+ counts greater than 400 x 10(6)/l, and 41 less than 400 x 10(6)/l, respectively (P less than 0.0001). A prospective study group of 33 subjects treated with zidovudine demonstrated a decrease in sIL-2R during therapy (base values 2113 +/- 1131 versus 1444 +/- 728 after 90 days of therapy; P less than 0.0007). The reduction of sIL-2R was greater in those subjects were p24 antigen became negative during treatment. sIL-2R therefore seems to be a useful tool in the monitoring of therapy with zidovudine.
Institute of Infectious Diseases, University of Milan, Italy.
M
M
Galli
A L
AL
Ridolfo
C
C
Balotta
A
A
Riva
F
F
Cocchi
M
M
Musicco
V
V
Albarello
M
M
Moroni
D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D005260:Female; D016655:HIV Core Protein p24 / Q000032:analysis; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D015497:HIV-1 / Q000378:metabolism*; D006716:Homosexuality; D006801:Humans; D008297:Male; D010949:Plasma / Q000737:chemistry; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000032:analysis* / Q000187:drug effects; D012995:Solubility; D019966:Substance-Related Disorders; D013997:Time Factors; D016896:Treatment Outcome; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use*
D016655:HIV Core Protein p24; D015375:Receptors, Interleukin-2; D015215:Zidovudine